Case report| Volume 22, P38-40, May 2018

Download started.


Severe multiple sclerosis reactivation after gonadotropin treatment

Published:February 28, 2018DOI:


      • Gonadotropin-treatment is considered a safer option for MS-patients than GnRH agonists.
      • We present a patient with a nearly fulminant relapse after starting gonadotropin-treatment.
      • The case demonstrates a safety concern regarding gonadotropin-treatment in MS-patients.


      Several reports indicate increased disease activity in patients with multiple sclerosis (MS) undergoing assisted reproductive techniques (ART), in the form of gonadtopin releasing hormone (GnRH) agonists. Other forms of ART treatments, like gonadotropin-treatment, have therefore been considered a safer option for MS-patients. We present a patient who despite being completely clinically and radiologically stable for eight years during disease modifying therapy experienced a nearly fulminant disease course almost immediately after starting gonadotropin-treatment, indicating that this form of follicle stimulating treatment could also be a major risk factor for MS disease activity.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Correale J.
        • Farez M.F.
        • Ysrraelit M.C.
        Increase in multiple sclerosis activity after assisted reproduction technology.
        Ann. Neurol. 2012; 72 (Epub 2012 Oct 3): 682-694
        • Ghadiri M.
        • Fitz-Gerald L.
        • Rezk A.
        • et al.
        Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
        Mult. Scler. 2017; 23: 1225-1232
        • Hatcher S.E.
        • Waubant E.
        • Nourbakhsh B.
        • Crabtree-Hartman E.
        • Graves J.S.
        Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment.
        JAMA Neurol. 2016; 73 (Jul 1): 790-794
        • Hellwig K.
        • Correale J.
        Artificial reproductive techniques in multiple sclerosis.
        Clin. Immunol. 2013; 149: 219-224
        • Vermersch P.
        • Radue E.W.
        • Putzki N.
        • et al.
        A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo.
        Mult. Scler. J. Exp. Transl. Clin. 2017; 3 (eCollection 2017)(2055217317730096)
        • Vukusic S.
        • Marignier R.
        Multiple sclerosis and pregnancy in the 'treatment era'.
        Nat. Rev. Neurol. 2015; 11: 280-289